CD34/QBEND 10 immunostaining in bone marrow biopsies: An additional parameter for the diagnosis and classification of myelodysplastic syndromes

European Journal of Haematology

Volumn 64, Issue 2, 2000, Pages 71-79

  Baur, Audrey S ^a   Meugé Moraw, Christiane ^a   Schmidt, Pierre Michel ^b   Parlier, Valérie ^b   Jotterand, Martine ^b   Delacrétaz, Françoise ^a  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bone marrow; Bone marrow biopsy; CD34 antigen; Immunohistochemistry; Myelodysplastic syndromes

Indexed keywords

CD34 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMYELOCYTE; REFRACTORY ANEMIA; ADOLESCENT; BIOPSY; BONE MARROW; CELL COUNT; CHEMISTRY; CHILD; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLASSIFICATION; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; INFANT; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; REFRACTORY ANEMIA WITH EXCESS BLASTS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BIOPSY; BONE MARROW; CELL COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 0033623460     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90047.x     Document Type: Article

References (42)

1. 1. Janssen JWG, Buschle M, Layton M, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989;73:248-254.
2. 2. List AF, Jacobs A. Biology and pathogenesis of the myelodysplastic syndromes. Semin Oncol 1992;19:14-24.
3. 3. Okada M, Okamoto T, Kanamaru A, Kaishita E. Clonal analysis in MDS (refractory anemia) by FISH and X-chromosome inactivation pattern using PCR. Proc Am Soc Hematol 1995;86:799a.
4. 4. Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Internat J Hematol 1996;63: 265-278.
5. 5. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425-433.
6. 6. Bennett JM, Catovski D, Daniel MT, et al. , the French-American-British (FAB) cooperative group: Proposals for the classification of myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
7. 7. Jotterand M, Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leukemia Lymphoma 1996;23:253-266.
8. 8. Delacrétaz F, Schmidt PM, Piguet D, Bachmann F, Costa J. Histopathology of myelodysplastic syndromes. Am J Clin Pathol 1987;87:180-186.
9. 9. Tricot G, De Wolf-Peeters C, Hendrickx B, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 1984;57:423-430.
10. 10. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of ALIP in myelodysplastic syndromes. Br J Haematol 1984;58:217-125.
11. 11. Bender JG, Unverzagt KL, Walker DE, et al. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991;77: 2591-2596.
12. 12. Civin C, Strauss LC, Brovall C, Fackler MJ, Schwatrz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised again KG-1a cells. J Immunol 1984;133:157-165.
13. 13. Greaves MF, Brown J, Molgaard HV, et al. Molecular features of CD34: a hemopoietic progenitor cell-associated molecule. Leukemia 1992;6(Suppl 1):31-36.
14. 14. Greaves MF, Titley I, Colman SM, et al. CD34 cluster workshop report. In: Schlossman S, ed. Leucocyte Typing V, London: Oxford University Press, 1994;840-846.
15. 15. Sutherland DR, Steward AK, Keating A. The CD34 antigen: molecular features and potential clinical applications. Stem Cells 1993;11(Suppl 3):50-57.
16. 16. Sawada K. Proliferation and differentiation of myelodysplastic CD34+ cells. Leukemia Lymphoma 1996;22:43-51.
17. 17. Tohyama K, Ueda T, Yoshida Y, Nakamura T. Altered responses of purified blast cells from the myelodysplastic syndromes to colony-stimulating factors in vitro: comparison with normal cells. Exp Hematol 1994;22:539-545.
18. 18. Soligo D, Delia D, Oriani A, et al. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody. Leukemia 1991;5:1026-1030.
19. 19. Soligo D, Oriani A, Annaloro C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994;46:9-17.
20. 20. Sullivan SA, Marsden KA, Lowenthal RM, Jupe DM, Jones ME. Circulating CD34 cells: an adverse prognostic-factor in the myelodysplastic syndromes. Am J Hematol 1992;39:96-101.
21. 21. Oriani A, Annaloro C, Soligo D, Pozzoli E, Cortelezzi A, Lambertenghi-Deliliers G. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Br J Haematol 1996; 92:360-364.
22. 22. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
23. 23. Kanter-Lewensohn L, Hellström-lindberg E, Kock Y, Elmhorn-Rosenborg A, Öst A. Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. Eur J Haematol 1996;56:124-129.
24. 24. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients, enhancement by intraveinous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:1905-1914.
25. 25. Fenaux P, Estienne MH, Lepelley P, et al. Refractory anemia according to the FAB classification: a report on 69 cases. Eur J Haematol 1988;40:318-325.
26. 26. Groupe Français de Cytogénétique Hématologique. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet 1991;55:57-65.
27. 27. Worsley A, Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukemia: a modified Bourne-mouth score gives the best prediction of survival. Br J Haematol 1988;88:17-21.
28. 28. Hanson CA, Ross CW, Schnitzer B. Anti-CD34 immunoperoxydase staining in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. Hum Pathol 1992;23:26-32.
29. 29. Solary E, Casasnovas RE, Campos L, et al. and the Groupe d'Etude Immunologique des Leucémies (GEIL). Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD34+/DR-phenotypes with shorter survival. Leukemia 1992;6:393-399.
30. 30. Lima M, Teixeira dos A, Morais S, et al. Immunophenotypic characteristics of acute leukemia after myelodysplastic syndromes. Sangre 1995;40:49-52.
31. 31. Gale RE, Wheadon H, Goldstone AH, Burnett AK, Linch DC. Frequency of clonal remission in acute myeloid leukemia. Lancet 1993;341:138-142.
32. 32. Delacrétaz F, Spertini O, Schmidt PM, Grob JP. Dysmegacaryopoiesis predicting response to therapy in acute myeloid leukemia. A histologic and clinical study. Pathol Res Pract 1991;187:290-295.
33. 33. Goasguen JE, Büchner T, Hiddemann W, et al. Prognostic importance of myeloid dysplastic features in AML. Blood 1994;82 Suppl.1:124a.
34. 34. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes: new proposals. Br J Haematol 1995;91:612-617.
35. 35. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993; 66:117-122.
36. 36. Orazi A, Albitar M, Heerema NA, Haskins S, Neiman R. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol 1997;107:268-274.
37. 37. Maciejewski JP, Anderson S, Katevas P, Young NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 1994;87:227-234.
38. 38. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991;78:161-166.
39. 39. Lambertenghi-Deliliers G, Annaloro C, Oriani A, Soligo D, Pozzoli E, Polli EE. Prognostic relevance of bone marrow biopsy in myelodysplastic syndromes. Ann Hematol 1993;66:85-91.
40. 40. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992;48:208-214.
41. 41. Maschek H, Gutzmer R, Choritt H, Georgii A. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol 1994; 53:280-287.
42. 42. Dickstein JI, Vardiman JW. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol 1993;99:513-525.